Healthcare / Medical Instruments & SuppliesASX
$0.35
+0.04 (+12.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $6.4M · quality 42.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$54M
P/E
N/A
•EV/EBITDA
12.0x
↓ROE
-4.2%
↓Gross Margin
38.1%
↓Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+15.7%
FCF CAGR
—
FCF margin
4.1%
FCF / Net income
-1.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $166.5M · net income $-4.5M · FCF $6.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $166.5M | $166.5M | $155.0M | $162.2M | $107.6M |
| Net Income | $-4.5M | $-4.5M | $-25.3M | $1.9M | $1.7M |
| EBITDA | $8.1M | $8.1M | $-20.9M | $14.2M | $4.5M |
| EPS | -0.03 | -0.03 | -0.17 | 0.01 | 0.01 |
| Gross Margin | 38.1% | 38.1% | 40.4% | 41.4% | 39.6% |
| Operating Margin | 2.1% | 2.1% | 0.2% | 5.8% | 5.2% |
| Net Margin | -2.7% | -2.7% | -16.3% | 1.2% | 1.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.55 | 0.47 | 0.57 |
| Current Ratio | 2.23 | 2.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $6.7M | $6.7M | $6.4M | $998000.00 | $-677000.00 |
| Returns | |||||
| ROE | -4.2% | -4.2% | -24.6% | 1.5% | 1.5% |
| Valuation | |||||
| P/E | — | — | — | 141.67 | 162.40 |
| EV/EBITDA | 12.00 | 12.00 | — | 21.80 | 72.58 |
| P/B | 0.51 | 0.51 | 1.49 | 1.99 | 2.38 |
| Growth & Yield | |||||
| Revenue Growth | 7.4% | 7.4% | -4.4% | 50.7% | — |
| EPS Growth | 82.5% | 82.5% | -1483.3% | -4.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-51.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.17 → -0.03
Residual
-51.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.